Korro Bio price target lowered to $100 from $115 at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Korro Bio (KRRO) to $100 from $115 and keeps a Buy rating on the shares. The firm sees Korro “as somewhat insulated from the market turmoil that rocked genetic medicines stocks this week.” While the was down as much as 26% in response to Vinay Prasad’s FDA appointment, this was mostly unwarranted, as KRRO-110 will not be reviewed by Dr. Prasad’s division, the analyst tells investors in a research note.